About Us

Reactivating Pathways to Healing

Caeregen Therapeutics is focused on discovering and developing novel drug therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompanies normal cellular and tissue development

Caeregen Therapeutics Leadership Team


December 8, 1946 – October 21, 2022. Dr. Trese was a great and inspirational leader, friend, and colleague whose warmth, wit, and generosity of spirit knew no boundaries.

Michael T. Trese, MD

Co-Founder and Chief Technology Officer

PhD in Molecular Genetics and Microbiology (UF)− Director of Pediatric Retinal Disease Molecular Genetics Laboratory at Oakland University Eye Research Institute.

Kimberly A. Drenser, MD PhD

Co-Founder and Chief Science Officer

Associated Retinal Consultants, Royal Oak, MI−President, Pediatric Retinal Research Foundation−Extensive clinical trial experience.

Antonio Capone, Jr, MD

Co-Founder and Chief Medical Officer
Capone D 400×400

Deep drug development back-ground, having ushered >25 drugs from various phases of development to commercial/clinical use−Former CEO/President, Multiple Myeloma Research Foundation.

Walter M. Capone, MBA

Chief Executive Officer and President
Wendy Dailey

Over 30 years conducting eye research. Spanning basic, translational and product development.

Wendy Dailey, B.S.

Research Manager

Scientific Advisory Board


Expert in age-related macular degeneration Vice Chair for Research and founder of the Center for Advanced Vision Science, University of Virginia

Jayakrishna Ambati, MD


Expert in diabetic retinopathy Director of Beetham Eye Institute at Joslin Diabetes Center, Harvard Medical School

Lloyd-Paul Aiello, MD PhD


Extensive innovations in intravitreal, gene and surgical adjuvant drug therapy. Founding Director of the Byers Eye Institute at Stanford

Mark S. Blumenkranz, MD MMS


Discovered vascular endothelial growth factor (VEGF), Senior Deputy Director, Basic Science at UC San Diego

Napoleone Ferrara, MD


Expert in retinopathy of prematurity and vascular growth mechanisms. Professor of Ophthalmology, Harvard Medical School

Lois H. Smith, MD PhD


Research Partners & Institutions

Industry Partners

Investors & Funding


Learn more about investing in our innovation.

News & Insights